Olswang advises Convergence Pharmaceuticals on its acquisition by Biogen Idec
26 January 2015
International law firm Olswang is proud to announce 31 of its lawyers have been recognised by Thomson Reuters in its 2014 London Super Lawyers and Rising Stars lists.
18 December 2014
International law firm Olswang has announced that Niall McAlister joined the firm on 29 September as a corporate partner in its London office. Niall will further strengthen the firm's top tier Life Sciences sector group.
03 October 2014
International TMT law firm Olswang has advised MoPowered, a leading mobile commerce enabler, on its admission to trading on the London Stock Exchange's Alternative Investment Market (AIM). The placing, which was oversubscribed, raised £4.0 million in total, with gross cash proceeds for the Company of £3.64 million. MoPowered's market capitalisation on admission, based on the placing price, was approximately £15.8 million.
18 December 2013
Olswang hosts private dinner with Viscount Younger of Leckie, UK Parliamentary Under Secretary of State for Intellectual Property
International TMT law firm Olswang has hosted a private dinner at its London office on Thursday 28 November 2013, with esteemed guest Viscount Younger of Leckie, UK Parliamentary Under Secretary of State for Intellectual Property at the Department for Business, Innovation & Skills.
29 November 2013
International law firm Olswang is proud to announce 28 of its attorneys have been recognised by Thomson Reuters in its 2013 London Super Lawyers and Rising Stars lists. Olswang is also delighted to announce Partner Eleni Skordaki has been listed in the Top 50 Women in London.
18 March 2013
Olswang, one of only 3 band 1 IP firms according to leading legal directory Chambers & Partners UK (2013 edition, London), has strengthened its leading Life Sciences practice with the arrival of patent expert Andrew Farquharson to its London office.
08 November 2012
Olswang recognised as one of a small handful of "go to" firms for IP by leading legal directory Chambers UK
Olswang, the international law firm and European leader in technology, media and telecommunications, has been recognised by leading legal directory Chambers & Partners as one of only three band 1 IP firms (London) in its 2013 UK edition.
07 November 2012
06 June 2012
23 March 2012
07 February 2012
15 December 2011
He has significant experience representing those clients within the life sciences and technology fields having acted recently on some of the most significant licensing transactions in the life sciences industry. In connection with his life sciences practice Stephen also advises clients on UK and EU regulatory matters within that sector.
On trade marks Stephen advises leading brand owners on the exploitation, protection and enforcement of their trade mark portfolios.
On the contentious side, Stephen has been involved in a number of leading patent cases including representing Lonza Biologics in the Kirin-Amgen v. TKT litigation, the University of California in proceedings brought by Dendron and Boston Scientific in the Conor v. Angiotech litigation.
Stephen is an Honorary Teaching Fellow at the University of Manchester's school of Pharmacy and Pharmaceutical Studies. He is currently an examiner for one of the papers for CIPA (Patent Attorneys) and ITMA (Trade Mark Attorneys) students and has given many external lectures on topics including IP audits, licensing, research and development agreements and injunctions.
He has been listed as one of IAM's Top 250 Patent Licensing specialists since 2010.
Olswang LLP’s life sciences department is co-led by Stephen Reese, who advised Fujifilm Kyowa Kirin Biologics on the establishment of a joint venture with AstraZeneca.
Stephen Reese advises on large-scale licensing, partnering and spin-out transactions in the sector. Clients say he is "extremely smart, very detail-oriented and makes sure everything is thought through and works."
Olswang LLP is particularly known in the market for its transactional and IP litigation capabilities. Stephen Reese co-leads the practice. The practice advised the shareholders of Convergence Pharmaceuticals on its acquisition by Biogen Idec.
Stephen has been recognised by Thomson Reuters in its 2014 London Super Lawyers lists.
Stephen Reese has a comprehensive IP practice within the life sciences sector, and handles advisory, transactional and contentious work. Sources say he is "very detail-oriented" and "a very good negotiator."
Olswang LLP draws on its IP, technology and transactional capabilities to handle patent protection and litigation as well as cross-border commercial deals. It advised Vectura Group on a global licensing deal with UCB Celltech, and acted for Resolution Chemicals in a patent dispute against Lundbeck, which settled before trial. IP lawyer Stephen Reese heads the department.
Olswang LLP draws on its media sector and trade mark capabilities in acting for clients such as ITV, Dentsu Aegis Network, Microsoft and M&C Saatchi. The trade mark group includes Stephen Reese, who recently advised Soho House Group on global portfolio management matters.
Olswang has an almost unrivalled understanding of, and commitment to, the media, entertainment and digital media space. The team here is recognised as a leading copyright and trade mark portfolio management practice. It also has one of the largest patent attorney offerings within aUKlaw firm, and has considerably strengthened its patent litigation offering. Key clients include ITV, Sky and Vodafone.
KEY INDIVIDUALS Stephen Reese is one of the lead partners managing Vodafone's global trade mark portfolio, and he also handles trade mark and branding work for the Richard Caring Group, which owns upmarket clubs and restaurants Le Caprice, The Ivy and Soho House.
Olswang has an admirably broad, standalone life sciences practice which advises companies and institutions on all facets of the market. As well as sophisticated IP and patent litigation, the group has noted strengths in all elements of commercial and transactional matters which underpin the industry. Clients include Convergence Pharmaceuticals, GlaxoSmithKline and MVM Life Science Partners.
KEY INDIVIDUALS Stephen Reese works largely on the commercial and transactional side of the life sciences industry, helping a variety of companies manage their patent estates and assisting clients with IP licensing agreements.
The firm coordinates Sky's international brand protection and enforcement programme as well as acting for Vodafone, ITV and Microsoft. Stephen Reese is recommended.
Olswang LLP is recommended for IP and commercial matters, providing 'added-value advice with a good contextual knowledge of the sector'. Practice head Stephen Reese gives 'sensible, pragmatic, commercial advice that you can trust' in relation to transactional and patent litigation matters.
Developing a cross-disciplinary life sciences practice that draws on the firm's strengths in patent and trade mark concerns. Capable in dealing with a wide range of issues, from advisory work to litigation.
Stephen Reese is singled out for his knowledge and attention to detail, as well as his ability to provide pragmatic advice.
Although perhaps better known for its soft IP practice, Olswang also has a formidable patent function that makes it a convincing contender in this space. With licensing, litigation and prosecution all on offer, it can provide a breadth of service that few competitors can match. This comprehensive capacity is twinned with an international outlook; and as the firm expands further into Europe, clients of all levels are seeking its counsel. "Outstanding litigator" Michael Burdon heads the IP group and also advises on protection, enforcement and the exploitation of portfolios.
Stephen has been recognised by Thomson Reuters in its 2013 London Super Lawyers lists.
Olswang's capabilities span IP, licensing, venture capital and transactional matters. Stephen Reese acted for the management on the spin-out of Autifony Therapeutics from GlaxoSmithKline. Reese also advised Vectora on a global licensing deal with Sandoz. The team also includes patent attorney Robert Stephen; and Campbell Forsyth, who joined from Forsyth Simpson and is 'a very diligent lawyer who consistently provides creative input to problems' on the patent litigation side.